RxDoctor Payments Data

Christopher Watts, MD

Infectious Disease · Douglasville, GANPI 1194884916

Payments from drug & device makers

$167in general payments, 2019–2025

Across 10 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$49
  • Gilead$41
  • Aroa Biosurgery Incorporated$34
  • AbbVie$19
  • Merck$13
  • Melinta Therapeutics, LLC$12

What the payments were for

  • Food & beverage$9356%
  • Education$7344%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$167 in reported general payments places this provider in the 30th percentile of 260 infectious disease providers in Georgia.

See all infectious disease providers in Georgia

Medicare billing

Part B allowed, 2024
$176,061
Medicare patients
273
Services billed
1,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala278$1,132,878
GenvoyaElviteg/Cob/Emtri/Tenof Alafen43$178,529
TriumeqAbacavir/Dolutegravir/Lamivudi40$161,282
TivicayDolutegravir Sodium61$143,763
CabenuvaCabotegravir/Rilpivirine25$142,653
DescovyEmtricitabine/Tenofov Alafenam48$116,387
PrezcobixDarunavir/Cobicistat34$91,165
IsentressRaltegravir Potassium39$85,153
JulucaDolutegravir/Rilpivirine17$68,334
OdefseyEmtricitab/Rilpiviri/Tenof Ala13$46,957
PifeltroDoravirine11$21,955
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df13$12,022
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)29$6,409
Daptomycin19$3,649
Zidovudine33$3,502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$41$1,427,795369 claims
MerckIsentress, Pifeltro$13$107,10950 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 260 infectious disease providers in Georgia.

Other infectious disease in Douglasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →